Trial Summary
What is the purpose of this trial?
The research study is being conducted to test how a specialized type of Positron Emission Tomography (PET/CT) scan could potentially be useful in diagnosing or monitoring treatment in people with Parkinson's disease. If the subject decide to be in this study he/she will have a PET/CT scans using an imaging drug called 18F-NOS which will be used to measure inflammation in the brain.
Eligibility Criteria
This trial is for people aged 18-75 with Parkinson's disease or healthy individuals interested in brain inflammation research. Participants must understand the study and agree to its procedures. Those with neuropsychiatric disorders can join if it doesn't risk their safety or participation, as judged by an investigator.Inclusion Criteria
History of diagnosis of probable idiopathic PD derived from UK Brain Bank Diagnostic criteria(1) per neurologist review.
I was diagnosed with Parkinson's Disease over 3 years ago.
Subjects with known neuropsychiatric disorder may be eligible if, in the opinion of an investigator, the psychiatric condition would not compromise subject safety or successful participation in the study.
See 5 more
Treatment Details
Interventions
- [18F]NOS (Imaging Agent)
Trial OverviewThe study tests a PET/CT scan using a tracer called 18F-NOS to detect brain inflammation, which could help diagnose or monitor Parkinson's disease treatment effectiveness.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: Patient with Parkinson DiseaseExperimental Treatment1 Intervention
Subject should have a history of diagnosis of probable idiopathic PD derived from UK Brain Bank Diagnostic criteria per neurologist review.
Subject must have been diagnosed with Parkinson's Disease at least 3 year prior to enrollment.
Group II: Healthy ControlExperimental Treatment1 Intervention
Subject must be a Healthy.
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
University of PennsylvaniaPhiladelphia, PA
Loading ...
Who Is Running the Clinical Trial?
University of PennsylvaniaLead Sponsor